New data suggest that vildagliptin is a safe and efficient therapy for new-onset diabetes after transplantation (NODAT). In this phase II, randomized, placebo-controlled trial, which included 33 kidney transplant recipients, vildagliptin therapy resulted in substantial improvements in levels of 2-h plasma glucose (derived using an oral glucose tolerance test) and HbA1c from baseline, at 3 months of follow-up.
References
Haidinger, M. et al. Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation—a randomized, double-blind, placebo-controlled trial. Am. J. Transplant. 10.1111/ajt.12518
Rights and permissions
About this article
Cite this article
Vildagliptin—a novel treatment option for NODAT. Nat Rev Nephrol 10, 64 (2014). https://doi.org/10.1038/nrneph.2013.266
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2013.266